BRCA1 and ovarian carcinoma: Nonetheless, even if blood FEAT increases in non-cancerous diseases, serial measurements of blood FEAT might be useful for the follow-up of high-risk individuals such as patients with BRCA1/2 mutations for development of breast and ovarian cancers [46].